The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.